Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD
- PMID: 24321790
- DOI: 10.1016/S2213-2600(12)70055-3
Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD
Comment on
-
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.Lancet Respir Med. 2013 Mar;1(1):51-60. doi: 10.1016/S2213-2600(12)70052-8. Epub 2012 Dec 6. Lancet Respir Med. 2013. PMID: 24321804 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
